Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-04-10
2007-04-10
Zeman, Mary K. (Department: 1631)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S828000, C424S184100, C424S185100, C424S277100, C436S501000, C436S064000, C436S813000, C435S007100
Reexamination Certificate
active
09636801
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer.
REFERENCES:
patent: 5082767 (1992-01-01), Hatfield et al.
patent: 1033401 (2000-09-01), None
patent: WO 99/25877 (1999-05-01), None
patent: WO-99/63008 (1999-12-01), None
patent: WO 99/63088 (1999-12-01), None
patent: WO 00/12758 (2000-03-01), None
patent: WO 00/55629 (2000-09-01), None
patent: WO 00/73454 (2000-12-01), None
patent: WO 00/76531 (2000-12-01), None
patent: WO 01/16318 (2001-03-01), None
patent: WO 01/18542 (2001-03-01), None
patent: WO 01/40269 (2001-06-01), None
patent: WO 01/57272 (2001-08-01), None
patent: WO 01/94641 (2001-12-01), None
patent: WO 02/02587 (2002-01-01), None
patent: WO 02/02624 (2002-01-01), None
patent: WO 02/10187 (2002-02-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO 02/16581 (2002-02-01), None
Biochemistry. Lehninger, A. (1970) Worth Publishers, New York, pp. 57-62 and 718.
Nagata et al. BBRC (1999) vol. 261, pp. 445-451.
Bookman et al., “Biological therapy of ovarian cancer: Current directions,”Seminars in Oncology, 25(3):381-396, 1998.
Gillespie et al., “Mage, Bage and Gage: Tumour antigen expression in benign and malignant ovarian tissue,”British Journal of Cancer, 78(6):816-821, Sep., 1998.
Heller et al., “Discovery and analysis of inflammatory disease-related genes using cDNA microarrays,”Proc. Natl. Acad. Sci. USA 94:2150-2155, Mar., 1997.
Ishikawa et al., “Prediction of the coding sequence of unidentified human genes. The complete sequence of 100 new cDNA clones from brain which can code for large proteins i vitro,”DNA Res., 5:169-176, 1998.
Jin et al., “Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1,”Cell 93:81-91, Apr. 3, 1998.
Köhler et al., “Immotherapy of Ovarian Carcinoma with the Monoclonal Anti-Idiotype Antibody ACA125—Results of the Phase LB Study,”Gebrutshilfe und Fraenheilkunde, 58(4):180-186, Apr. 1998+(English Abstract).
Ma et al., “Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses,”Journal of Pharmaceutical Sciences, 87(11):1375 1378, Nov., 1998.
Parker et al., “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains,”The Journal of Immunology 152(1):163-175, Jan. 1, 1994.
Peoples et al., “Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides,”Annals of Surgical Oncology, 5(8):743-750, Dec., 1998.
Schena et al., “Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes,”Proc. Natl. Acad. Sci., 93:10614-10619, Oct., 1996.
LifeSeq Accession No. 027245.1, May 1999.
Life Seq Accession No. 2798803H1, Mar. 1997.
Frankel, A.E. et al., “Targeted Toxins,”Clinical Cancer Research 6: 326-334, Feb. 2000.
GenBank Accession No. AA075632, Dec. 23, 1997. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. AA404225, Aug. 8, 1997. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. NM—024626, Sep. 3, 2004. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. NP—078902, Sep. 3, 2004. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. XM—018334, Oct. 16, 2001. Available at www.ncbi.nlm.nih.gov/entrz .
GenBank Accession No. XP—018334, Oct. 16, 2001. Available at www.ncbi.nlm.nih.gov/entrz .
Algate Paul A.
Fanger Gary R.
Fling Steven P.
King Gordon E.
Mitcham Jennifer L.
Corixa Corporation
Seed IP Law Group PLLC
Zeman Mary K.
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3790246